Literature DB >> 17694757

Controlled release of simvastatin acid using cyclodextrin inclusion system.

Masao Yoshinari1, Kenichi Matsuzaka, Sadamitsu Hashimoto, Kazuyuki Ishihara, Takashi Inoue, Yutaka Oda, Takaharu Ide, Teruo Tanaka.   

Abstract

Simvastatin acid (SVA) has been reported to stimulate bone formation by increasing expression of BMP-2 in osteoblasts. Due to their multi-functional characteristics and bioadaptability, cyclodextrins (CDs) are capable of forming inclusion complexes with many drugs by including a whole drug molecule inside their cavity. In the present study, we prepared SVA/CD inclusion complex solutions with different pH values. These were then used to determine their SVA release behavior after coating on titanium substrates, as well as to clarify the characteristics of SVA/CD complexes per se. Results showed that the lower the pH value of the solution, the lower the release kinetics of SVA. Besides, the amount of crystalline complexes in the coatings increased with decrease in pH. These results suggested that the release rate of SVA depended on two factors: pH of the solution and concomitant crystallinity of the coating.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694757     DOI: 10.4012/dmj.26.451

Source DB:  PubMed          Journal:  Dent Mater J        ISSN: 0287-4547            Impact factor:   2.102


  7 in total

1.  The Evaluation of Therapeutic Efficacy and Safety Profile of Simvastatin Prodrug Micelles in a Closed Fracture Mouse Model.

Authors:  Yijia Zhang; Zhenshan Jia; Hongjiang Yuan; Anand Dusad; Ke Ren; Xin Wei; Edward V Fehringer; P Edward Purdue; Aaron Daluiski; Steven R Goldring; Dong Wang
Journal:  Pharm Res       Date:  2016-05-10       Impact factor: 4.200

Review 2.  Advanced technologies for oral controlled release: cyclodextrins for oral controlled release.

Authors:  Paulo José Salústio; Patrícia Pontes; Claúdia Conduto; Inês Sanches; Catarina Carvalho; João Arrais; Helena M Cabral Marques
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

3.  Simvastatin prodrug micelles target fracture and improve healing.

Authors:  Zhenshan Jia; Yijia Zhang; Yen Hsun Chen; Anand Dusad; Hongjiang Yuan; Ke Ren; Fei Li; Edward V Fehringer; P Edward Purdue; Steven R Goldring; Aaron Daluiski; Dong Wang
Journal:  J Control Release       Date:  2014-12-24       Impact factor: 9.776

4.  Role of prostaglandin pathway and alendronate-based carriers to enhance statin-induced bone.

Authors:  Yeonju Lee; Xinming Liu; Ali Nawshad; David B Marx; Dong Wang; Richard A Reinhardt
Journal:  Mol Pharm       Date:  2011-04-05       Impact factor: 4.939

5.  Lovastatin release from polycaprolactone coated β-tricalcium phosphate: effects of pH, concentration and drug-polymer interactions.

Authors:  Solaiman Tarafder; Kelly Nansen; Susmita Bose
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2013-03-14       Impact factor: 7.328

6.  Polycaprolactone-coated 3D printed tricalcium phosphate scaffolds for bone tissue engineering: in vitro alendronate release behavior and local delivery effect on in vivo osteogenesis.

Authors:  Solaiman Tarafder; Susmita Bose
Journal:  ACS Appl Mater Interfaces       Date:  2014-06-17       Impact factor: 9.229

7.  Fast disintegrating crystalline solid dispersions of simvastatin for incorporation into orodispersible tablets.

Authors:  Ritesh M Pabari; Asha Jamil; John G Kelly; Zebunnissa Ramtoola
Journal:  Int J Pharm Investig       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.